Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutic (NQ: UTHR )

378.13 +1.13 (+0.30%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutic

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why Shares of MannKind Corporation Are Falling This Morning
Investors are hyperventilating after a delay for its inhaled medicine. 
Via The Motley Fool
FDA Declines MannKind - United Therapeutics' Formulated Treprostinil For Lung Disease
The FDA has issued a complete response to United Therapeutics Corporation (NASDAQ: UTHR) regarding the marketing application for Tyvaso DPI for pulmonary... 
Via Benzinga
Exposures Product Safety
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
Acceleron Stock Heats Up On $11 Billion Takeover Rumor; So, Who's The Buyer?
A biotech working in lung and blood diseases, as well as cancer, could be acquired. 
Via Investor's Business Daily
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
Stocks That Hit 52-Week Highs On Friday
During the morning session on Friday, 178 stocks hit new 52-week highs. Noteworthy Points: Microsoft (NASDAQ:MSFT) was the largest firm on a market cap basis to set... 
Via Benzinga
United Therapeutics-MannKind's Formulated Tyvaso Shows Benefit In Pulmonary Hypertension Patients
United Therapeutics Corporation (NASDAQ: UTHR) has presented new clinical data from the BREEZE study evaluating Tyvaso DPI (treprostinil) in patients with pulmonary... 
Via Benzinga
Innovators in Pharma Sectors See Potential, Promise in Providing Improved Treatments
Via FinancialNewsMedia
Why United Therapeutics Blasted 14% Higher Today
Every one of the company's products booked a revenue gain in Q2. 
Via The Motley Fool
United Therapeutics Corporation (UTHR) Q2 2021 Earnings Call Transcript
UTHR earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
88 Biggest Movers From Yesterday
Gainers BeyondSpring Inc. (NASDAQ: BYSI) shares climbed 176% to close at $26.58 on Wednesday in reaction to topline data from DUBLIN-3 Phase 3 trial evaluating plinabulin in... 
Via Benzinga
United Therapeutics: Q2 Earnings Insights
Shares of United Therapeutics (NASDAQ:UTHR) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share increased 11.14% over the past... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Mostly lower Ahead Of General Motors Earnings
Pre-open movers U.S. stock futures traded mostly lower in early pre-market trade after the Dow Jones surged around 280 points in the previous session. Investors are awaiting... 
Via Benzinga
Topics Stocks
Exposures US Equities
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,... 
Via Benzinga
Exposures COVID-19 Product Safety
Earnings Scheduled For August 4, 2021
Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter. • Vericel (NASDAQ:VCEL) is expected to... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2021
Upgrades CL King upgraded the previous rating for Compass Minerals International Inc (NYSE: 
Via Benzinga
MannKind - United Therapeutics' Formulated Treprostinil Under FDA Review For Pulmonary Hypertension
MannKind Corporation (NASDAQ: MNKD) and United Therapeutics Corporation (NASDAQ: UTHR) have announced that the FDA has accepted for review the marketing... 
Via Benzinga
Exposures Product Safety
Price Over Earnings Overview: United Therapeutics
Looking into the current session, United Therapeutics Inc. (NASDAQ:UTHR) is trading at $193.48, after a 2.35% decrease. Over the past month, the stock fell by 3.61... 
Via Benzinga
The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24) Bristol-Myers Squibb Company... 
Via Benzinga
10 Biggest Price Target Changes For Thursday
Rosenblatt lifted the price target on Qorvo Inc (NASDAQ: QRVO) from $175 to $200. Qorvo shares rose 0.8% to $184.01 in pre-market trading. Needham boosted HubSpot Inc (NASDAQ:... 
Via Benzinga
United Therapeutics Corp (UTHR) Q1 2021 Earnings Call Transcript
UTHR earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
United Therapeutics: Q1 Earnings Insights
Shares of United Therapeutics (NASDAQ:UTHR) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were down 3.32% year over year to $3.... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Gain; General Motors Earnings In Focus
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Nasdaq dipped more than 260 points in the previous session. Investors are awaiting earnings... 
Via Benzinga
Stocks That Hit 52-Week Highs On Wednesday
Before 10 a.m. ET on Wednesday, 140 companies hit new 52-week highs. Noteworthy Highlights: The largest company by market cap to set a new 52-week high was... 
Via Benzinga
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 22) AtriCure, Inc. (NASDAQ:... 
Via Benzinga
Stocks That Hit 52-Week Highs On Tuesday
This morning 147 companies reached new 52-week highs. Noteworthy Mentions: UnitedHealth Group (NYSE:UNH) was the company with the largest market cap to set a new 52... 
Via Benzinga
The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) Alexion Pharmaceuticals,... 
Via Benzinga
The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 20) Alexion Pharmaceuticals,... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.